Cardiovascular disease in autoimmune rheumatic diseases
I Hollan, PL Meroni, JM Ahearn, JWC Tervaert… - Autoimmunity …, 2013 - Elsevier
Various autoimmune rheumatic diseases (ARDs), including rheumatoid arthritis,
spondyloarthritis, vasculitis and systemic lupus erythematosus, are associated with …
spondyloarthritis, vasculitis and systemic lupus erythematosus, are associated with …
[HTML][HTML] The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus
Antiphospholipid syndrome (APS) is the association of thrombosis and/or pregnancy
morbidity with antiphospholipid antibodies (aPL). Thirty to forty percent of systemic lupus …
morbidity with antiphospholipid antibodies (aPL). Thirty to forty percent of systemic lupus …
Cardiac manifestations of antiphospholipid syndrome with focus on its primary form
T Kolitz, S Shiber, I Sharabi, A Winder… - Frontiers in …, 2019 - frontiersin.org
Antiphospholipid syndrome (APS) is a multisystem autoimmune disease most commonly
associated with recurrent arterial and venous thromboembolism and recurrent fetal loss …
associated with recurrent arterial and venous thromboembolism and recurrent fetal loss …
Accelerated atherosclerosis in patients with SLE—mechanisms and management
BJ Skaggs, BH Hahn, M McMahon - Nature Reviews Rheumatology, 2012 - nature.com
Rapid-onset cardiovascular disease (CVD) is a major concern for many patients with
systemic lupus erythematosus (SLE). Cardiovascular events occur more frequently and with …
systemic lupus erythematosus (SLE). Cardiovascular events occur more frequently and with …
Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots
As the coronavirus disease 2019 (COVID-19) pandemic, which is caused by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly worldwide, it …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly worldwide, it …
Coronary heart disease in young adults
JB Rubin, WB Borden - Current atherosclerosis reports, 2012 - Springer
Despite the recent decline in mortality from coronary heart disease (CHD), this disease
remains the leading killer of US adults of all ages. CHD in young adults is not as well …
remains the leading killer of US adults of all ages. CHD in young adults is not as well …
Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity. A critical updated review
The role of antiphospholipid antibodies (aPL) associated with cardiovascular diseases has
been extensively studied in autoimmune patients, however it was largely unknown whether …
been extensively studied in autoimmune patients, however it was largely unknown whether …
Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays
A Vikerfors, AB Johansson, JT Gustafsson… - …, 2013 - academic.oup.com
Objectives. To evaluate the agreement and performance of two tests for aPLs with regard to
association with manifestations of the APS in patients with SLE. Methods. We investigated …
association with manifestations of the APS in patients with SLE. Methods. We investigated …
Epidemiology of antiphospholipid syndrome: macro-and microvascular manifestations
Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by
thrombotic and non-thrombotic macro-and microvascular manifestations and pregnancy …
thrombotic and non-thrombotic macro-and microvascular manifestations and pregnancy …
Long-term outcome of patients with antiphospholipid syndrome who undergo percutaneous coronary intervention
L Perl, A Netzer, E Rechavia, T Bental, A Assali… - Cardiology, 2012 - karger.com
Objectives: Patients with antiphospholipid antibody syndrome (APS) have an increased risk
of atherothrombotic complications. There are limited data regarding the outcome of patients …
of atherothrombotic complications. There are limited data regarding the outcome of patients …